Drugs / Gardasil-4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT07256912 | Apr 2026 → Dec 2028 expected | — | International Agency for Research on Cancer | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05266898 Background | Nov 2022 → Dec 2025 overdue | HIV infectious disease, cervical intraepithelial neoplasia, human papilloma virus infection, intraepithelial neoplasia +1 | Louisiana State University Health Sciences Center in New Orleans | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gardasil-4 | “Gardasil-4 single dose” NCT07256912 ↗ |
| Modality | Vaccine | “Subunit vaccine against four (6, 11, 16, 18) or nine (6, 11, 16, 18, 31, 33, 45, 52, 58) genotypes of human papillomavirus.” NCT05266898 ↗ |